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Abstract
Background—Minimizing time to Human Immunodeficiency Virus (HIV) viral suppression is 
critical in pregnancy. Integrase strand transfer inhibitors (INSTIs), like raltegravir, are known to 
rapidly suppress plasma HIV ribonucleic acid (RNA) in nonpregnant adults. There is limited data 
in pregnant women.
Objective—We describe time to clinically relevant reduction in HIV RNA in pregnant women 
using INSTI-containing and non-INSTI-containing ART options.
Study Design—We conducted a retrospective cohort study of pregnant HIV-infected women in 
the U.S. from 2009 to 2015. We included women who initiated antiretroviral therapy (ART), 
intensified their regimen or switched to a new regimen due to detectable viremia (HIV RNA > 
40c/mL) at ≥ 20 weeks gestation. Among women with a baseline HIV RNA permitting one-log 
reduction, we estimated time to one-log RNA reduction using the Kaplan-Meier estimator 
comparing women starting/adding an INSTI in their regimen versus other ART. To compare 
groups with similar follow-up time, we also conducted a subgroup analysis limited to women with 
≤14 days between baseline and follow-up RNA data.
Results—This study describes 101 HIV-infected pregnant women from 11 U.S. clinics. Seventy-
five percent (76/101) women were not taking ART at baseline; 24 were taking non-INSTI 
containing ART, and 1 received zidovudine monotherapy. Thirty-nine percent (39/101) of women 
started an INSTI-containing regimen or added an INSTI to their ART regimen. Among 90 women 
with a baseline HIV RNA permitting one-log reduction, the median time to one-log RNA 
reduction was 8 days [Interquartile Range (IQR): 7, 14] in the INSTI group versus 35 days [IQR: 
20, 53] in the non-INSTI ART group (p<0.01). In a subgroup of 39 women with first and last RNA 
measurements ≤14 days apart, median time to one-log reduction was 7 days [IQR: 6, 10] in the 
INSTI group versus 11 days [IQR: 10, 14] in the non-INSTI group (p<0.01).
Conclusion—ART that includes INSTIs appears to induce more rapid viral suppression than 
other ART regimens in pregnancy. Inclusion of an INSTI may play a role in optimal reduction of 
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HIV-RNA for HIV-infected pregnant women presenting late to care or failing initial therapy. 
Larger studies are urgently needed to assess the safety and effectiveness of this approach.
Keywords
HIV; pregnancy; integrase inhibitors
Introduction
In the past twenty years, tremendous progress has been made in the United States in the field 
of HIV and pregnancy. Current U.S. Perinatal HIV Guidelines, the American College of 
Obstetricians and Gynecologists, and the World Health Organization (WHO) now 
recommend initiation of antiretroviral therapy (ART) as early as possible during pregnancy 
due to prolific amounts of data demonstrating lower risk of mother-to-child HIV 
transmission (MTCT) with earlier viral suppression.1 In women with suppressed HIV viral 
loads, the risk of mother-to-child HIV transmission (MTCT) is less than 2%, however, the 
higher a woman’s viral load at the time of delivery, the more likely her chance of 
transmitting to her infant.2,3 Unsuppressed HIV viral load at the time of delivery remains 
one of the most important risk factors for perinatal HIV transmission.4–6 Despite massive 
public health efforts in the US, perinatal HIV transmission still occurs, often among women 
who present late in pregnancy with a high viral load due to antiretroviral drug resistance 
issues, non-adherence to prescribed ART or late entry into HIV care.6 Challenges also 
remain in settings where provider adherence to HIV perinatal guidelines may be 
suboptimal.5
Options for women who present with high viral loads close to the time of delivery are 
limited to planning a cesarean delivery and potentially switching the women to an 
antiretroviral that may rapidly decrease her viral load. Raltegravir, an integrase strand 
transfer inhibitor (INSTI) antiretroviral agent, has been shown to rapidly decrease time to 
virologic suppression and, in combination with other antiretroviral drugs, is recommended 
as a first-line option for nonpregnant patient populations.7 In August 2015, raltegavir was 
upgraded to a preferred agent for use of INSTI-based combination ART in pregnancy.1 Prior 
to that, it was considered an alternative option in pregnant women, although clinically it has 
been used in women who required rapid virologic suppression late in pregnancy. Data from 
published case series demonstrate rapid reductions in viral load during pregnancy, although 
no guidelines currently recommend it as a first line therapy to rapidly suppress HIV viral 
loads among women close to the time of delivery.8–12 In this study we describe time to 
clinically relevant reduction in HIV RNA in pregnant women using INSTI-containing and 
non-INSTI-containing ART options.
Materials and Methods
We conducted a retrospective cohort study of pregnant HIV-infected women receiving 
prenatal care at 11 tertiary care centers in the United States between July 1, 2009 and June 
30, 2015. The cohort included HIV-infected pregnant women with HIV RNA levels ≥ 48 
copies/mL at ≥ 20 0/7 weeks gestation and their HIV-exposed neonates. Women were 
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included if they had an intervention to change their treatment during this time period. 
Women were described as ART initiators if they were not currently taking ART. This group 
included women who were either ART naïve or had stopped taking previously prescribed 
medications. Women who were currently taking ART were described as either changing 
(stopping current ART and starting a new regimen) or intensifying their regimen (adding 
new medications to existing ART regimen). Women were excluded if they did not have at 
least 2 HIV RNA measurements - one corresponding to the time prior to the intervention and 
at least one after the intervention.
A request for participation was enlisted on the University of California San Francisco 
(UCSF)-Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Reproductive 
Infectious Disease listserv. Researchers from 11 academic medical centers agreed to 
collaborate. Institutional Review Board approval or exemption was completed at each of the 
11 sites. Demographic data, medical history, laboratory testing of mother and infant pairs 
were collected via chart review and recorded on a standardized form at each site. An AIDS 
diagnosis was defined as history of CD4 count of less than 200 cells/μl. Each site reviewed 
its own records for inclusion and exclusion criteria. De-identified data were sent to the 
University of North Carolina.
Baseline characteristics of women with an INSTI-containing intervention versus a non-
INSTI-containing intervention were compared using standard statistical tests, including chi-
square or Fisher’s exact tests for categorical factors and Wilcoxon rank sum tests for 
continuous measures. Our primary outcome of interest was time (in days) from ART 
intervention to a one-log decrease in viral load. Time from ART intervention until a one-log 
decrease in viral load as well as cumulative incidence curves, were estimated using the 
Kaplan-Meyer estimator. Women who did not achieve a one-log decrease in viral load were 
censored. Women who had a baseline viral load greater than 398 copies/mL (2.6 log10 
copies/mL) were eligible for the analysis for a reduction in one log10, since the lower limit 
of assay detection was 40 (1.6 log10 copies/mL). The log-rank test was used to test for 
differences in time to each outcome comparing those initiating/adding an INSTI and those 
initiating/adding a non-INSTI regimen.
Results
Baseline characteristics
One hundred and one pregnant women met eligibility criteria from 11 sites. Characteristics 
of all pregnant women at baseline (time of ART intervention at ≥ 20 weeks gestation) are 
reported in Table 1. The median gestational age at time of ART intervention was 29.0 weeks 
(interquartile range [IQR]: 26.0–33.6). The median viral load at time of ART intervention 
was 16,030 copies/mL (IQR: 3,370–46,271). Sixty-three (62%) of the pregnant women were 
diagnosed with HIV prior to the index pregnancy and the remaining 38 (38%) were 
diagnosed during the index pregnancy.
An INSTI was initiated/added in 39/101 (39%) women (Table 1). There were no significant 
differences in age, race/ethnicity, parity, initial HIV RNA, or maternal comorbidities 
between the INSTI and non-INSTI groups (Table 1). The median gestational age at inclusion 
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in the study was 33 weeks in the INSTI-group compared to 27 weeks in the non-INSTI 
group (p<0.01). Twenty-three (60%) women who initiated/added an INSTI-based regimen 
had an AIDS diagnosis compared to twenty (32%) women who initiated/added other ART 
(p<0.01). The majority of women had genotype testing performed either prior to pregnancy 
(28%) or during pregnancy (70%).
ART regimens
ART initiation—Of the 101 pregnancies, 76 (76%) women were not taking any ART 
regimen prior to intervention. All ART regimens that were initiated during the study 
included two nucleoside reverse transcriptase inhibitors (NRTIs) such as tenofovir/
emtricitabine or zidovudine/lamivudine. Of these 76 women, 6 women initiated on 2NRTI
+INSTI-based regimens (5 raltegravir, 1 elvitegravir/cobistat). Fourteen women initiated 
2NRTIs + INSTI + PI (6 lopinavir/raltegravir, 3 atazanavir/raltegravir, 1 atazanavir/
dolutegravir, 3 darunavir/raltegravir, 1 darunavir/raltegravir). Forty-nine women inititied 
2NRTI+PI-based regimens (37 lopinivir, 6 atazanavir, 6 darunavir). When used, all protease 
inhibitors (PIs) were boosted with ritonavir. One woman initiated a 2NRTI+ non-nucleoside 
reverse transriptase inhibitor (NNRTI)-based regimen (efavirenz) and 5 women initiated a 
single tablet regimen of tenofovir/emtricitabine combined with the NNRTI rilpivirine. One 
initiated a 3-NRTI based regimen (abacavir/lamivudine/zidovudine).
Regimen change or intensification—Of the 25 remaining women who were taking any 
antiretroviral medications at the time of inclusion in our study, 23 had been prescribed a 
ritonavir-boosted PI-based regimen (9 on atazanavir, 6 on darunavir, 8 on lopinavir) in 
addition to dual NRTIs. One woman had been prescribed abacavir/lamivudine/zidovudine 
and one was presented taking zidivudine only. At the time of inclusion of the study, 18 
women changed regimens completely and 7 had drugs added to intensify their regimen. Of 
the 18 who changed regimens, 12 changed to INSTI-based regimens and 6 changed to other 
regimens. Of the 7 who had drugs added to their regimen, all had an INSTI (6 raltegravir, 1 
dolutegravir) added.
One log10 reduction in HIV RNA or viral load
Ninety-two (91%) of 101 women were eligible for inclusion in the analysis for a one-log 
reduction in viral load. Eighty-eight percent (81/92) of the women eligible for this analysis 
had at least a one log10 reduction by their last viral load measure before delivery.
The median time to a visit where viral load was reduced by one log10 varied based on 
whether or not women initiated a INSTI-based regimen or non-INSTI regimen (8 days [IQR: 
7, 14] versus 35 days [IQR: 20, 53] respectively, p<0.01, Figure 1a). Of note, women on 
INSTI-based regimens had an average of one viral load measurement every 13 days, while 
the average rate of assessment among women on non-INSTI-based regimens was one viral 
load measurement every 23 days [rate ratio [95% CI]=1.8 (1.4, 2.2)]. Therefore, in order to 
compare groups with similar levels of follow-up and viral load assessment, we conducted a 
subgroup analysis among women with a follow-up visit after an initial baseline assessment 
of less than 14 days (n=39). Among this subgroup, the median time to a visit where there 
was a one log10 reduction in viral load varied based on whether they initiated an INSTI-
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based regimen or non-INSTI regimen (7 days [IQR: 6, 10] and 11 [IQR: 10, 14] respectively, 
Figure 2; log-rank p <0.01).
Delivery
The median time from ART intervention to delivery was 57 days (IQR: 34–84) and the 
median reduction in viral load from ART intervention to last viral load measurement was 
14,779 copies/mL (IQR: 3,290–42,786) (Table 2). Thirty-five (35%) women’s viral loads 
were suppressed to <40 copies/mL based on their last viral load measurement reported 
before delivery. Although there was not a statistically significant difference in the amount of 
viral load reduction in the two groups, women in the INSTI group had a shorter ART 
duration prior to delivery (p<0.01) and lower CD4 nadir during pregnancy (p=0.02,Table 2).
There were no reports of laboratory abnormalities or complications attributed to ART use in 
the cohort. Nine of 101 women were diagnosed with preeclampsia/gestational hypertension 
and six of 101 presented with premature rupture of membranes (PPROM or PROM) or 
preterm labor. A total of 21/101 (21%) women delivered prematurely (< 37 weeks 
gestation).
Follow up data were available on 86/101 (85%) of the neonates from birth to at least 4 
months of age. Seventy of the neonates had sufficient results to be diagnosed as HIV-
uninfected. Fifteen neonates had only one negative HIV RNA result. One neonate was 
diagnosed as HIV-infected. The mother was diagnosed with HIV during the index pregnancy 
which was complicated by depression. She was initiated on zidovudine/lamivudine/boosted 
lopinavir at 31 weeks with a viral load of 21,685 copies/mL. A second viral load of 2,171 
copies/mL was documented 42 days later at 37 weeks gestation, when she was delivered by 
elective cesarean section due to preeclampsia. Of note, she had an active genital HSV 
infection at 34 weeks. The neonate’s birth HIV DNA PCR testing was positive, and this was 
presumed to be an intrauterine infection. The following complications were observed in 
other neonates (count reported in parentheses): anemia (2), hyperbilirubinemia (1), club foot 
(1), group B streptococcal septicemia (1), respiratory syncytial virus (1), 
pseudohypoaldosteronism (1), upper respiratory infection (1), small for gestational age (2), 
hyperbilirubinemia (1), neonatal opiate withdrawal (1), and congenital heart defect (1).
Case reports of dolutegravir
Four of the 39 INSTI-based regimens included dolutegravir. Two patients initiated a 
dolutegravir-containing regimen (dolutegravir/darunavir/ritonavir/truvada and truvada/
atazanavir/ritonavir/dolutegravir), one patient switched from abacavir/atazanavir/ritonavir to 
dolutegravir/tenofovir/emtricitabine, and the last had dolutegravir added to her abacavir/
atazanavir/ritonavir regimen. The baseline viral load for these patients was 34,000, 2,000, 
14,554 and 46,271 copies/mL, respectively. All of their interventions occurred late in the 
third trimester (range 33–36 weeks), and all had only one follow-up viral load (range 6–8 
days). All four women experienced at least a one-log reduction in viral load to 1,080, 42, 20, 
3,485 copies/mL, respectively. No maternal side effects were noted; one neonate was small 
for gestational age and was diagnosed with hyperbilirubinemia. All neonates exposed to 
dolutegravir were HIV-uninfected.
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Comment
Principle findings
Our retrospective study demonstrates that a wide variety of ART regimens are prescribed 
across the U.S. for management of women whose HIV-1 viral load is not suppressed late 
pregnancy. This study supports previously published case reports of rapid decline in HIV-1 
viral load after treatment with INSTI-containing regimens.8,9,11,12 All of the observed ART 
regimens were effective in decreasing HIV viral load in a relatively short time period, but the 
addition of an integrase inhibitor suppressed viral load more quickly. This is consistent with 
prior literature describing the effect of INSTI-based ART in pregnancy, however, a strength 
of our study is that we compared INSTI- and non-INSTI-containing ART directly.8,9,11–14 
Additionally, we describe the clinical practice of using regimens that did not fall under 1st 
line recommended maternal treatment at the time of the study.1 According to these data, 
pregnant HIV-infected women are prescribed newer potent ART options or regimens that are 
convenient once-a-day options, likely in order to promote adherence. Our study also 
includes one of the few clinical descriptions of dolutegravir use in pregnancy.
Meaning of observations as it relates to other studies and research implications
This study contributes to the growing literature on raltegravir in pregnancy. Studies of 
pregnant HIV-infected women have described high rates of viral suppression, good tolerance 
to the medication, and ready cross-over into the placenta despite median raltegravir area 
under the curve concentrations that were 29–50% lower than non-pregnant women.15–17 The 
previous collection of case reports has also shown rapid decline in plasma viral loads similar 
to our study.15,16,18–2021,2223 A single case report described maternal hepatic toxicity, which 
diminished after discontinuation of raltegravir. Monitoring of transaminases should occur 
with INSTI use during pregnancy.24 Our study included 39 women exposed to an INSTI 
without apparent ART related side effects; however due to the retrospective nature of this 
study, there may be missing or unavailable data. Our sample size was smaller than the large 
studies needed to detect rare events. The national Antiretroviral Pregnancy Registry has not 
reported congenital anomalies or adverse neonatal outcomes associated with INSTI use in 
more than 350 pregnant women thus far.18 Dolutegravir and Elvitegravir are considered U.S 
Food and Drug Administration (FDA) pregnancy category B and Raltegravir is pregnancy 
category C.
Use of raltegravir was associated with a rapid decrease in viral load in our study. However, 
raltegravir is a twice-daily medication, which may be associated with noncompliance. 
Raltegravir was studied as a once daily medication (800 mg daily) compared to twice daily 
(400 mg bid) in a double-blinded randomized controlled noninferiority study – both in 
combination with tenofovir and emtricitabine in non-pregnant adults.25 This study 
demonstrated longer time to viral suppression with once-daily dosing, particularly in 
individuals with HIV RNA >100,000 copies/ml or CD4 counts <200 cells/mm3 prior to 
initiating therapy. Among other participants, the response rate for once-daily raltegravir was 
similar to other recommended ART regimens. The authors were not able to comment on 
which regimen would be superior if there were drug adherence challenges.26 Notably, 80% 
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of the participants were male, and pregnant women were excluded. Further study of once-
daily dosed INSTI’s in pregnant women should be pursued.
There are insufficient data to recommend use of other INSTI’s such as dolutegravir or 
elvitegravir in pregnancy.18 One of the major benefits of dolutegravir and elvitegravir is their 
once-daily dosing schedule. A single case report describes pharmacokinetics of dolutegravir 
in the newborn after maternal exposure.27 Our study includes 4 women who took 
dolutegravir and 1 woman who took elvitegravir. All of these women demonstrated rapid 
viral load reduction and no adverse maternal or neonatal outcomes that could linked to 
medication exposure. Further studies on the safety and efficacy of these regimens in 
pregnancy are needed as the once a day dosing of these medications is appealing.
Clinical Implications
While HIV testing and treatment campaigns have dramatically reduced vertical infections in 
resource-rich settings, they still occur.5 Limited access to prenatal care, inadequate HIV 
testing in pregnancy, and psychosocial stressors and mental health issues affecting adherence 
continue to cause delayed diagnoses and/or late engagement in HIV care. A case series of 
perinatal HIV transmissions between 2005 to 2012 reported that 24 of 27 transmission were 
related to failure in healthcare delivery and uptake.5 Vigilant screening for HIV in pregnancy 
and resources to support pregnant HIV-infected mothers during pregnancy must be in place 
to eliminate MTCT.
Providers must also be aware of resources and updates to current guidelines1 Raltegravir is 
now a preferred agent if an INSTI is used in pregnancy.1 Though dosed twice daily, 
raltegravir is well tolerated and has a high barrier to developing drug resistance. Intravenous 
administration of intrapartum zidovudine continues to be recommended in women whose 
viral loads have not been consistently suppressed during pregnancy and elective cesarean 
delivery should be offered to women whose viral load is ≥ 1,000 copies/mL.1 However, late 
term or intrapartum interventions will not prevent antepartum transmission as in the case of 
the one known HIV-infected neonate in the cohort. Only early, aggressive control of viremia 
will prevent intrauterine infections. The Perinatal HIV/AIDS hotline (888-448-8765) is 
available to care providers 24 hours a day for consultation regarding HIV-infected pregnant 
mothers and neonates in the U.S.
Limitations
Our retrospective study is limited in that we could not control for timing of viral load 
measurements. Our results are potentially biased by differential outcome assessment. As 
indicated by our subgroup analysis of women who had two viral load measures less than 14 
days apart, we may have seen a more rapid drop in the non-INSTI group in the larger 
analysis if viral load measurements had occurred on a similar timeline as the INSTI group. 
Ideally, if there had been more time prior to the completion of the pregnancies, we could 
have made a more direct comparison of time to viral suppression between the two groups 
rather than being limited to a one-log decrease in viremia. However, a reduction in viral load 
is a significant factor in decreasing risk of MTCT.28 The risk of perinatal transmission 
decreased as viral load decreased in United Kingdom/Ireland population-based surveillance. 
RAHANGDALE et al. Page 8
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MTCT rates were 0.09%, 1.0%, and 2.6% for women with viral loads of <50, 50–399, and 
400–999 copies/mL, respectively (p<0.001).28 There was a difference in timing of regimens 
(33.6 weeks for INSTI; 27.5 weeks for other regimens) in our study; this may imply that 
there was a bias in choosing INSTI’s in women who were later in pregnancy or had higher 
viral loads. Though all centers had access to INSTI’s, we also do not have data on the 
rationale for choice of regimen. The small sample size of this study also limited the ability to 
control for other potential confounders and explore issues such the preterm labor rate of 
21%. Despite these limitations, this study also contributes important data on a difficult to 
study population.
Conclusions
These study findings should direct future research efforts. The INSTI class of medication 
could play a significant role not only in resource-rich settings, but also in low-resource 
settings where women may only access prenatal care in the 3rd trimester or not start ART 
until close to delivery. A well-tolerated, rapid-acting ART option with a high threshold for 
development of resistance mutations could be ideal in these settings to reduce risk of MTCT. 
Decreasing viremia prior to delivery may modify the risk not only of infant HIV infection, 
but also of adverse maternal outcomes by decreasing need for elective cesarean delivery. 
Additionally, the potential role of INSTI-containing regimens to rapidly reduce viral load in 
settings where maternal complications, preterm labor or premature rupture of membranes 
may shorten pregnancy unexpectedly is appealing. It is critical that providers caring for HIV-
infected pregnant women are aware of INSTI use as a potential strategy for rapid virologic 
suppression in pregnancy which is ideal at any gestational age to prevent both antepartum 
and intrapartum infection. Further data is needed regarding the efficacy, safety and 
tolerability of INSTIs during pregnancy.
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FIGURE 1. 
Cumulative incidence of one log10 viral load reduction among HIV-infected pregnant 
women initiating antiretroviral therapy in late pregnancy.
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FIGURE 2. 
Cumulative incidence of one log10 viral load reduction among HIV-infected pregnant 
women initiating antiretroviral therapy in late pregnancy among subgroup with comparable 
follow up.
RAHANGDALE et al. Page 13
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
RAHANGDALE et al. Page 14
TABLE 1
Characteristics of HIV-infected pregnant women at late pregnancy antiretroviral therapy intervention, 2009–
2015.
Overall
(N=101)
INSTI
(N=39)
Other
(N=62)
p-value
Race & Ethnicity
 White, non-Hispanic 16 (16) 5 (13) 11 (18) 0.47
 White, Hispanic 10 (10) 4 (11) 6 (10)
 Black 73 (72) 28 (72) 45 (73)
 Other 2 (2) 2 (5) 0 (0)
Parity*
 0 38 (38) 17 (44) 21 (34) 0.63
 ≥1 62 (61) 22 (56) 40 (65)
Maternal Age (years)* 27 (23, 32) 29 (23, 34) 26 (23, 31) 0.33
Gestational Age (weeks) 29.0 (26.0–33.6) 33.6 (29.9–36.1) 27.5 (25.4–30.7) <0.01
Body Mass Index (kg/m2) 29.6 (26.3–35.2) 27.7 (24.4–35.0) 30.5 (26.6–35.3) 0.26
No ART at baseline† 76 (75) 20 (51) 56 (90) <0.01
Initial HIV RNA
 (log10) 4.2 (3.5–4.7) 4.3 (3.5–4.9) 4.1 (3.4–4.6) 0.21
 (copies/mL) 16,030 (3,370–46,271) 21,278 (3,370–71,660) 14,033 (2,500–35,570)
AIDS Diagnosis* 43 (43) 23 (60) 20 (32) <0.01
Maternal Comorbidity
 Hepatitis B 5 (5) 2 (5) 3 (5) 0.95
 Hepatitis C 10 (10) 2 (5) 8 (13) 0.31
 Substance Use 19 (19) 7 (18) 12 (19) 0.86
 Depression/mental illness 28 (28) 14 (36) 14 (23) 0.15
Categorical variables are expressed as N (%) and continuous variables are expressed as median (IQR).
*One missing observation.
†Women on ART were only included if they were not suppressed after 20 weeks gestation and thus additional ART was added to their regimen or 
their regimen was switched.
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TABLE 2
Characteristics of HIV-infected pregnant women at delivery, 2009–2014.
Overall
(N=101)
INSTI
(N=39)
Other
(N=62)
p-value
Total
Mode of delivery
 Vaginal 49 (49) 23 (59) 26 (42) 0.05
 Elective C-section 36 (36) 14 (36) 22 (35)
 Labored C-section 16 (16) 2 (5) 14 (23)
Gestational Age (weeks)
 <37 21 (21) 7 (18) 14 (23) 0.58
 37–41 80 (79) 32 (82) 48 (77)
Pregnancy CD4 nadir (cells/μl) 275 (164–458) 195 (82–397) 297 (196–463) 0.02
Duration of ART (days)* 57 (34–84) 35 (8–59) 71 (47–86) <0.01
Median VL reduction 14,779 20,650 12,926 0.21
 IQR (3,290–42,786) (3,350–59,610) (2,480–35,442)
 range (25–633,885) (25–633,885) (71–143,023)
Categorical variables are expressed as N (%) and continuous variables are expressed as median (IQR).
*
Time from ART intervention to delivery; does not include ART use prior to late pregnancy intervention.
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